Ontology highlight
ABSTRACT: Introduction
Immunogenicity has emerged as a challenge in the development of vaccines against coronavirus disease of 2019 (COVID-19). Immunogenicity is a determinant of the efficacy and safety of vaccines. This systematic review and associated meta-analysis summarized and characterized the immunogenicity of COVID-19 vaccines in randomized controlled trials (RCTs).Methods
Relevant RCTs were systematically sourced from different medical databases in August 2021. The risk ratios and mean differences with 95% confidence intervals were calculated.Results
Of 2,310 papers, 16 RCTs were eligible for review. These RCTs involved a total of 26,698 participants (15,292 males and 11,231 females). The pooled results showed a significant difference in the geometric mean titer between the vaccinated and control groups in favor of the vaccine group after 1 and 2 months of follow-up, for the young age group (18 - < 55y), and with different doses (P < 0.001). The difference in the older age group (>55y) was insignificant (P = 0.24). The seroconversion rate of spike neutralizing antibodies favored the vaccine groups 1 or 2 months after vaccination (P < 0.001). The seroconversion rate of the vaccine group was significantly different (P < 0.001) from that of the control group.Conclusions
Vaccination elicits immunogenicity in the follow-up period for all age groups and at low and large doses. Therefore, people should be encouraged to receive vaccines currently being offered. A boost dose has been asserted for the elderly.
SUBMITTER: Vasconcelos ZS
PROVIDER: S-EPMC9870285 | biostudies-literature | 2023
REPOSITORIES: biostudies-literature
Vasconcelos Zanair Soares ZS Salem Hany Abdulateif HA Veiga Sâmia Pimenta SP Lima Fabiola Estefany Botelho de FEB Gonçalves César Rogério da Silva CRDS Santos Eliane Carvalho Dos ECD Brandão Alba Regina Jorge ARJ Couceiro Kátia Nascimento KN Guerra Jorge Augusto de Oliveira JAO Guerra Maria das Graças Vale Barbosa MDGVB
Revista da Sociedade Brasileira de Medicina Tropical 20230123
<h4>Introduction</h4>Immunogenicity has emerged as a challenge in the development of vaccines against coronavirus disease of 2019 (COVID-19). Immunogenicity is a determinant of the efficacy and safety of vaccines. This systematic review and associated meta-analysis summarized and characterized the immunogenicity of COVID-19 vaccines in randomized controlled trials (RCTs).<h4>Methods</h4>Relevant RCTs were systematically sourced from different medical databases in August 2021. The risk ratios and ...[more]